Journal Club  by unknown
Kidney International (2006) 70       833
journal  c lubhttp://www.kidney-international.org
© 2006 International Society of Nephrology
Kidney International (2006) 70, 833–834. doi 10.1038/sj.ki.5001818
Dendritic cells mediate tolerance 
to vascularized grafts
Th e primary goal in clinical transplantation is tolerance 
to transplant antigens. Although much has been learned 
over the past decade about the various cell populations 
involved in transplant rejection, the cell sub-populations 
involved in the induction and maintenance of transplant 
tolerance remain unidentifi ed. Th is is due in part to the 
diffi  culty in defi ning the interactions between diverse 
antigen-presenting cells and T-cell subsets with disparate 
traffi  cking patterns. Now, an article by Ochando et al.1 
has identifi ed plasmacytoid dendritic cells (pDCs) as 
phagocytic antigen-presenting cells essential for tolerance 
to vascularized cardiac allograft s. Tolerizing pDCs acquired 
alloantigen in the allograft  and then moved through the 
blood to home to peripheral lymph nodes. In the lymph 
node, alloantigen-presenting pDCs induced the generation 
of CCR4+CD4+CD25+Foxp3+ regulatory T cells (Treg cells). 
Depletion of pDCs or prevention of pDC lymph node 
homing inhibited peripheral Treg-cell development and 
tolerance induction, whereas adoptive transfer of tolerized 
pDCs induced Treg-cell development and prolonged graft  
survival. Th us, in tolerogenic conditions, alloantigen-
presenting pDCs homed to the lymph nodes, where they 
mediated alloantigen-specifi c Treg-cell development and 
allograft  tolerance. In an accompanying commentary,2 
Qizhi Tang and Jeff rey A Bluestone point out that dendritic 
cells, in addition to initiating immune responses, also 
infl uence regulatory T-cell activity and homeostasis. Th ey 
note that functional outcomes of dendritic cell–T cell 
interactions depend on the immunological context of their 
encounter. (1Nat Immunol 2006; 7: 652–662. 2Nat Immunol 
2006; 7: 551–553)
Detlef Schlöndorﬀ 
Molecular profiling of transplanted 
organs improves clinical diagnoses
Changes in the function of transplanted organs are oft en 
assessed by histological analysis of small biopsies. Although 
this is still considered the gold standard for diagnosis of 
acute transplant rejection, comparisons between histological 
diagnoses of biopsies and of the whole organ at autopsy in heart 
transplants show that the overall sensitivity of endomyocardial 
biopsy is only about 70%, and that a substantial number 
of rejections can be missed. In addition, infection of the 
transplanted organ may also occur, and histology of biopsies 
may not discriminate well between a rejection and an immune 
response involved in fi ghting infection. Yet discrimination 
is essential, because the treatment for the two conditions is 
diff erent. Morgun et al. tested whether molecular profi ling by 
microarray analysis of gene expression patterns would identify 
infections. Th ey studied cardiac allograft s as a model transplant, 
and Chagas’s disease (infection with Trypanosoma cruzi) as a 
model infection. In Latin America, many heart recipients receive 
transplants because of chronic heart failure resulting from 
Chagas’s disease, and relapse is one of the most frequent post-
transplantation complications. Th e authors analyzed mRNA 
amplifi ed from biopsy samples taken from heart recipients with 
cases of rejection, no rejection, or infection. Th ey found specifi c 
molecular profi les that discriminate among patients undergoing 
rejection, no rejection, or infection. A set of genes whose 
expression patterns were typical of acute rejection and another 
set of genes that discriminated between rejection and T. cruzi 
infection were identifi ed. Th ese sets revealed acute-rejection 
episodes up to 2 weeks earlier and trypanosome infection up to 
2 months earlier than did histological evaluation. When applied 
to raw data from other institutions, the two sets of predictive 
genes were able to accurately pinpoint acute rejection of lung 
and kidney transplants, as well as bacterial infections in kidneys. 
Th us, this approach may be useful for identifying infections that 
are universally encountered and for transplanted organs other 
than the heart. (Circ Res 2006; 98: 1564)
Juan Oliver
Nephritogenic lupus antibodies 
recognize fragments of apoptotic 
intraglomerular cells
Antibodies to double-stranded DNA (dsDNA) represent a 
classifi cation criterion for systemic lupus erythematosus, and 
sub-populations of these antibodies are involved in lupus 
nephritis. It is unclear what separates nephritogenic from 
non-nephritogenic anti-dsDNA antibodies. Further, it is still 
unresolved whether glomerular target antigens are constituted 
by nucleosomes or non-nucleosomal glomerular structures. It 
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has been previously shown that antibodies eluted from murine 
nephritic kidneys recognize nucleosomes. In a new study, 
Kalaaji et al. examined the structures that bind nephritogenic 
autoantibodies in vivo. Th ey used transmission electron 
microscopy, immune electron microscopy and colocalization 
immune electron microscopy together with antibodies to 
dsDNA, to histones and transcription factors, or to laminin. 
Th eir results indicate that glomerular basement membrane-
associated nucleosomes are the target structures for the 
nephritogenic autoantibodies. Furthermore, TdT-mediated 
dUTP nick end-labeling or caspase-3 assays demonstrate that 
lupus nephritis is linked to intraglomerular cell apoptosis. Th e 
data suggest that nucleosomes are released by apoptosis and 
associate with glomerular basement membranes, which may 
then be targeted by pathogenic anti-nucleosome antibodies. 
Th us, apoptotic nucleosomes may represent both inducer and 
target structures for nephritogenic autoantibodies in systemic 
lupus erythematosus. (Am J Pathol 2006; 168: 1779–1792)
Juan Oliver
Prevention of C5 activation 
ameliorates glomerulonephritis in 
factor H deficiency
Membranoproliferative glomerulonephritis (MPGN) type II 
(dense deposit disease) is an infl ammatory disease for which 
there is no eff ective therapy; about half of patients progress 
to end-stage renal failure within a decade. Th e disease is 
characterized by intramembranous glomerular basement 
membrane (GBM) deposits together with C3, C5 and C9 
staining along the GBM in the absence of immunoglobulin. 
Defi ciency of factor H (a serum protein that inhibits the 
alternative pathway of complement activation) in mice, 
pigs and humans is associated with MPGN type II. In 
factor H defi ciency, there are unhindered alternative-
pathway activation and markedly reduced C3 levels in 
plasma. MPGN has also been reported in individuals with 
dysfunctional C3 molecules and in an individual with an 
autoantibody against factor H. Patients with MPGN type 
II also develop macular drusen, a feature of age-related 
macular degeneration that has recently been associated with 
factor H mutations.
Abnormal factor H function appears to underlie the 
pathogenesis of many cases of human MPGN type II, but 
the role of other components of the alternative complement 
pathway has not been studied. Using factor H-defi cient mice 
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Morphological analyses of nephritic glomeruli of B/w16 by transmission 
electron microscopy and colocalization immune electron microscopy.
(Cfh –/–), which spontaneously develop MPGN that depends 
on activation of C3, Pickering et al. examined the role of C5 
activation in the development of the glomerulonephritis. 
Th ey found that mice defi cient in both C5 and factor H still 
developed MPGN but displayed reduced mortality and 
glomerular cellularity in comparison with mice defi cient in 
factor H alone. Second, to mimic disease fl ares that may occur 
in patients with MPGN, they investigated how Cfh –/– mice 
with MPGN responded to an additional nephrotoxic insult. 
Th ey found that these mice had increased susceptibility to 
heterologous nephrotoxic nephritis and that administration 
of a monoclonal anti-C5 antibody was protective. Th us, their 
data show a modifying pathogenic role for C5 activation in the 
development of spontaneous MPGN and in acute renal injury. 
Th ese fi ndings are relevant to the treatment of individuals 
with MPGN type II and C3 dysregulation. Th e authors suggest 
testing the effi  cacy of anti-human C5 antibody therapy. 
(Proc Natl Acad Sci USA 2006; 103: 9649–9654)
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